CRBP stock forecast, quote, news & analysis
Corbus Pharmaceuticals Holdings Inc is a clinical stage company focused on new therapies in oncology and obesity and is committed to helping people defeat serious illness by bringing inventive scientific approaches to well-understood biological pathways... Show more
Why Corbus Pharmaceuticals (CRBP) Stock Is Down -40% in the Last 30 Days
Key Takeaways
- Corbus Pharmaceuticals Holdings (CRBP) shares fell roughly 40% over the trailing 30 days, dropping from about $6.92 to near $4.15.
- The sell-off was driven primarily by investor disappointment in Phase 1b topline data for CRB-913, an oral obesity candidate that showed a placebo-adjusted 5% weight loss at 12 weeks.
- Over the last quarter, the stock has declined more than 50%, extending a broader multi-month downtrend.
- Wall Street's consensus rating remains a "Moderate Buy" with an average 12-month price target near $39.57, though individual analyst views diverge sharply.
- As of June 30, 2026, Corbus reported roughly $118 million in cash and investments alongside a wider-than-expected quarterly loss.
- For additional detail on valuation, results, and outlook, explore the Price Targets, Earnings, and Forecast pages.
- To track automated strategies and AI-driven signals across the market, visit the Trending AI Robots section.
Corbus Pharmaceuticals (CRBP) Company Overview and Market Position
Corbus Pharmaceuticals Holdings, Inc. is a clinical-stage biopharmaceutical company headquartered in Norwood, Massachusetts, developing novel therapies in oncology and obesity. The company's pipeline is built around three core programs: CRB-701, an antibody-drug conjugate (ADC) that targets Nectin-4 on cancer cells; CRB-913, a highly peripherally restricted cannabinoid type-1 (CB-1) receptor inverse agonist being developed as a once-daily oral treatment for obesity; and CRB-601, an anti-integrin monoclonal antibody designed to block TGF-beta activation in tumors.
As a pre-revenue, development-stage company, Corbus generates essentially no product sales and funds its operations through equity raises and cash on hand. Investors follow the stock for binary clinical catalysts: the obesity program positions the company against the large, rapidly growing market dominated by GLP-1 therapies from Eli Lilly and Novo Nordisk, while CRB-701 offers exposure to the ADC oncology space. This concentration of value in early-stage clinical data makes the stock highly volatile around trial readouts.
Corbus Pharmaceuticals (CRBP) Stock Price Performance: Last 30 Days vs. Quarter
Over the trailing 30 days, CRBP shares declined approximately 40%, falling from a closing price of about $6.92 in late September to roughly $4.15 in late October. The move was punctuated by sharp single-session drops and elevated trading volume, signaling a sustained repricing rather than a brief dip.
The quarterly picture is even weaker. Measured over the last three months, the stock is down more than 50%, falling from roughly $8.92 at the end of July to its current level. This extends a longer slide from earlier in 2026, when shares traded in the low double digits, and places the stock near its 52-week low. The persistent decline reflects a combination of a disappointing clinical data readout, continued cash burn, and a broader risk-off tone toward early-stage biotech names lacking near-term revenue.
What Drove CRBP Stock Price in the Last 30 Days
The dominant catalyst was the release of topline data from the CANYON-1 Phase 1b trial of CRB-913 in obesity. In mid-September 2026, Corbus reported that the 60 mg dose produced a placebo-adjusted mean weight loss of roughly 5% at 12 weeks, with dose-dependent results and no serious treatment-related adverse events. While the company described the results as statistically significant and clinically meaningful, the market judged the magnitude of weight loss as modest relative to injectable GLP-1 therapies, which have demonstrated substantially greater reductions. The stock fell sharply in the sessions following the announcement.
Secondary pressures compounded the move. A corporate presentation filed with the SEC in mid-October reiterated the CRB-913 data and highlighted a 42.9% confirmed objective response rate for CRB-701 in oropharyngeal cancer, but provided no new efficacy data to offset investor concerns. Separately, the company's latest quarterly loss of $1.81 per share came in wider than analyst expectations, and insider sales by the CEO and CFO at higher prices earlier in the year added to the cautious tone. Rising short interest and the stock's breach below key technical levels also contributed to continued selling pressure.
What Drove CRBP Stock Performance Over the Last Quarter
The broader three-month decline reflects a shift in investor expectations for Corbus's obesity franchise. Entering the period, optimism around CRB-913 as a potential non-incretin, oral alternative in the weight-loss market supported a higher valuation. The CANYON-1 readout deflated that thesis, as the observed efficacy was seen as insufficient to compete against established GLP-1 drugs without meaningfully differentiated safety or convenience advantages.
At the same time, the oncology program has yet to produce a major catalyst sufficient to re-anchor sentiment. Progress on CRB-701, including the initiation of the registrational TEMPO-1 trial, is viewed positively but remains early-stage. Against a backdrop of continued operating losses, limited insider buying, and a capital-intensive development roadmap, the market has progressively discounted the shares. Analyst targets remain far above the current price, highlighting a wide gap between long-term expectations and near-term market sentiment.
Trending AI Robots
Tickeron operates hundreds of AI-powered trading bots that actively trade thousands of tickers across a wide range of strategies. Only the top-performing and most relevant bots are featured in the curated Trending AI Robots section, giving traders a focused view of automated systems currently generating the strongest signals. These bots vary considerably in strategy, timeframe, and performance metrics, so investors can compare approaches before deciding which ones align with their own objectives. Exploring the section can offer a useful complement to fundamental research on names like CRBP.
CRBP Stock Forecast Drivers: What Investors Should Watch Next
Investors should monitor several factors in the months ahead. The company's next quarterly results, expected in mid-November 2026, will provide updated cash position, expense guidance, and management commentary on pipeline timing. Additional data presentations on CRB-913 at upcoming obesity-focused conferences are a key catalyst, as longer-duration or higher-dose results could reshape the efficacy narrative. Enrollment and execution of the TEMPO-1 registrational trial for CRB-701 will be closely watched, along with any updates on the Nectin-4 ADC program.
Broader considerations include the competitive dynamics of the obesity market, where oral candidates from larger pharmaceutical companies continue to advance, and the company's need to fund future trials. Macroeconomic conditions, including the interest-rate environment and risk appetite for pre-revenue biotech stocks, will also influence valuation. As with all clinical-stage companies, the outlook hinges on data quality, regulatory progress, and disciplined capital management.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
CRBP's MACD Histogram crosses above signal line
The Moving Average Convergence Divergence (MACD) for CRBP turned positive on October 22, 2026. Looking at past instances where CRBP's MACD turned positive, the stock continued to rise in 40 of 44 cases over the following month. The odds of a continued upward trend are 90%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where CRBP's RSI Oscillator exited the oversold zone, 31 of 48 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 65%.
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 45 of 61 cases where CRBP's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 74%.
Following a +28.01% 3-day Advance, the price is estimated to grow further. Considering data from situations where CRBP advanced for three days, in 227 of 280 cases, the price rose further within the following month. The odds of a continued upward trend are 81%.
CRBP may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The 50-day moving average for CRBP moved below the 200-day moving average on October 07, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where CRBP declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 87%.
The Aroon Indicator for CRBP entered a downward trend on November 10, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 8 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 64 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.581) is normal, around the industry mean (3.498). P/E Ratio (-0.502) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (440.869).
The Tickeron Price Growth Rating for this company is 93 (best 1 - 100 worst), indicating slightly worse than average price growth. CRBP’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CRBP’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a provider of drug development services
Industry Biotechnology